EUVIMEDEUVIMED entdecken
Open Access

Suppression of cathepsin K biomarker in synovial fluid as a free-drug–driven process

Bennett Ma iD, Gregg Wesolowski, Bin Luo, Traci Lifsted, Keith Wessner, Gary Adamson, Helmut Glantschnig, Laura S Lubbers

Journal of Circulating Biomarkers · 2019

DOI: 10.1177/1849454418821819 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Circulating Biomarkers, 2019. Verfasst von Bennett Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., West Point, PA, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cathepsin K (CatK) inhibitors exhibited chondroprotective and pain-reducing effects in animal models, however, improvements were relatively modest at dose levels achieving maximal suppression of CatK biomarkers in urine. In this report, a previously characterized CatK inhibitor (MK-1256) is utilized to explore the potential of reduced target engagement and/or suboptimal exposure (free drug) as limiting factors to the pharmacological potential of CatK inhibitors in the knee joint. Following oral administration of MK-1256 at a dose level achieving maximal inhibition of urinary biomarker (helical peptide) in dogs, full suppression of the biomarker in synovial fluid was observed. Subsequent tissue distribution studies conducted in dogs and rabbits revealed that MK-1256 levels in synovial fluid and cartilage were consistent with the free-drug hypothesis. Reasonable projection (within twofold) of drug levels in these tissues can be made based on plasma drug concentration with adjustments for binding factors. These results indicate that the previously observed efficacies in the animal models were not limited by compound distribution or target engagement in the knee tissues.

Schlagwörter

Stichwörter der Autor:innen

Cathepsin KMK-1256cartilageosteoarthritissynovial fluid

Autor:innen und Institutionen

  • Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., West Point, PA, USA.
  • Department of Bone Biology, Merck & Co., West Point, PA, USA.
  • Department of Pharmacology, Merck & Co., West Point, PA, USA.

ORCID-Profile: Bennett Ma

Förderung

  • Merck

Zitieren

APA

Ma, B., Wesolowski, G., Luo, B., Lifsted, T., Wessner, K., Adamson, G., Glantschnig, H., & Lubbers, L. S. (2019). Suppression of cathepsin K biomarker in synovial fluid as a free-drug–driven process. Journal of Circulating Biomarkers. https://doi.org/10.1177/1849454418821819

Vancouver

Ma B, Wesolowski G, Luo B, Lifsted T, Wessner K, Adamson G, et al. Suppression of cathepsin K biomarker in synovial fluid as a free-drug–driven process. Journal of Circulating Biomarkers. 2019. doi:10.1177/1849454418821819

BibTeX
@article{Ma2019,
  author = {Ma, Bennett and Wesolowski, Gregg and Luo, Bin and Lifsted, Traci and Wessner, Keith and Adamson, Gary and Glantschnig, Helmut and Lubbers, Laura S},
  title = {Suppression of cathepsin K biomarker in synovial fluid as a free-drug–driven process},
  journal = {Journal of Circulating Biomarkers},
  year = {2019},
  doi = {10.1177/1849454418821819}
}
Kostenlos starten →